Vimarsana
Biggest News Aggregation in the World

Page 2 - Temporary Equity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Temporary Equity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Temporary Equity Today - Breaking & Trending Today

SoFi Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results - Vimarsana News

SoFi Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results

29.01.2024 - SoFi Technologies, Inc. (NASDAQ: SOFI), a member-centric, one-stop shop for digital financial services that helps members borrow, save, spend, invest and protect their money, reported financial results today for its fourth quarter and fiscal year ...

Capital City Bank Group, Inc. Reports Fourth Quarter 2023 Results - Vimarsana News

Capital City Bank Group, Inc. Reports Fourth Quarter 2023 Results

TALLAHASSEE, Fla., Jan. 23, 2024 -- Capital City Bank Group, Inc. today reported net income attributable to common shareowners of $11.7 million, or $0.70 per diluted share, for the fourth quarter...

Verint Announces Q3 FYE 2024 Results - Vimarsana News

Verint Announces Q3 FYE 2024 Results

SaaS ARR up 11% Year-Over-Year Driven by Solid Bookings and Renewals Positive Leading Indicators with Significant Increase in Customer AI Adoption and SaaS Pipeline up More than 20%...

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results - Vimarsana News

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track ...

ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results - Vimarsana News

ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results

Key Corporate Highlights: Progressing toward Q1-2024 initiation of a proof-of-concept clinical trial with Cholesterol Efflux Mediatorâ„¢ VAR 200 in patients with diabetic kidney disease...